Jump to main content

Calcium channel blocker in patients with chronic kidney disease

Icons representing 記事
The cover of this title could differ from library to library. Link to Help Page

Calcium channel blocker in patients with chronic kidney disease

Persistent ID (NDL)
info:ndljp/pid/12289733
Material type
記事
Author
Shoko Ohnoほか
Publisher
Springer Nature
Publication date
2021-11-08
Material Format
Digital
Journal name
Clinical and experimental nephrology : official publication of the Japanese Society of Nephrology 26(3)
Publication Page
-
View Details

Notes on use at the National Diet Library

本資料は、掲載誌(URI)等のリンク先にある電子書籍・電子雑誌の提供元Webサイトなどから、本文を自由に閲覧できる場合があります。

Detailed bibliographic record

Summary, etc.:

[Background] Chronic kidney disease (CKD) is involved in a progressive deterioration in renal function over the years and is now a global public healt...

Holdings of Libraries in Japan

This page shows libraries in Japan other than the National Diet Library that hold the material.

Please contact your local library for information on how to use materials or whether it is possible to request materials from the holding libraries.

other

  • CiNii Research

    Search Service
    Digital
    You can check the holdings of institutions and databases with which CiNii Research is linked at the site of CiNii Research.

Bibliographic Record

You can check the details of this material, its authority (keywords that refer to materials on the same subject, author's name, etc.), etc.

Digital

Material Type
記事
Author/Editor
Shoko Ohno
Akira Ishii
Motoko Yanagita
Publication, Distribution, etc.
Publication Date
2021-11-08
Publication Date (W3CDTF)
2021-11-08
Periodical title
Clinical and experimental nephrology : official publication of the Japanese Society of Nephrology
No. or year of volume/issue
26(3)
Volume
26(3)
ISSN (Periodical Title)
1437-7799
ISSN-L (Periodical Title)
1437-7799
Text Language Code
eng
Persistent ID (NDL)
info:ndljp/pid/12289733
Collection (Materials For Handicapped People:1)
Collection (particular)
国立国会図書館デジタルコレクション > 電子書籍・電子雑誌 > その他
Acquisition Basis
オンライン資料収集制度
Date Accepted (W3CDTF)
2022-05-23T15:55:37+09:00
Date Captured (W3CDTF)
2022-05-16
Format (IMT)
application/pdf
Access Restrictions
国立国会図書館内限定公開
Service for the Digitized Contents Transmission Service
図書館・個人送信対象外
Availability of remote photoduplication service
Periodical Title (Persistent ID (NDL))
info:ndljp/pid/12289732
Data Provider (Database)
国立国会図書館 : 国立国会図書館デジタルコレクション

Digital

Summary, etc.
[Background] Chronic kidney disease (CKD) is involved in a progressive deterioration in renal function over the years and is now a global public health problem. Currently, reducing the number of patients progressing to end-stage renal failure is urgently necessary. Hypertension and CKD interact with each other, and good control of blood pressure (BP) can improve CKD patients’ prognosis. With the current global trend for more strict BP control, the importance of BP management and the need for medication to achieve this strict goal are increasing. Calcium channel blockers (CCBs), which target voltage-dependent calcium channels, are frequently used in combination with renin–angiotensin–aldosterone system inhibitors for CKD patients because of their strong BP-lowering properties and relatively few adverse side effects. Calcium channels have several subtypes, including L, N, T, P/Q, and R, and three types of CCBs, L-type CCBs, L-/T-type CCBs, and L-/N-type CCBs, that are available. Nowadays, the new functions and effects of the CCBs are being elucidated. [Conclusion] We should use different types of CCBs properly depending on their pharmacological effects, such as the strength of antihypertensive effects and the organ protection effects, taking into account the pathophysiology of the patients. In this article, the role and the use of CCBs in CKD patients are reviewed.
Access Restrictions
インターネット公開
Rights (production)
© The Author(s) 2021
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
References
Ablation of the N-type calcium channel ameliorates diabetic nephropathy with improved glycemic control and reduced blood pressure
Association between the size of healthcare facilities and the intensity of hypertension therapy: a cross-sectional comparison of prescription data from insurance claims data
Inhibition of N-type Ca[2+] channels ameliorates an imbalance in cardiac autonomic nerve activity and prevents lethal arrhythmias in mice with heart failure.
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)
Chronic kidney disease as a global public health problem: Approaches and initiatives – a position statement from Kidney Disease Improving Global Outcomes
Molecular and Functional Diversity of Voltage‐Gated Calcium Channels
Vasodilatory edema: A common side effect of antihypertensive therapy
KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease
Attenuation of renal fibrosis after unilateral ureteral obstruction in mice lacking the N-type calcium channel
Effects of Vasopeptidase Inhibition on Renal Function and Tubuloglomerular Feedback in Spontaneously Hypertensive Rats
Clinical studies on pharmacological treatment of hypertension in Japan
Investigational calcium channel blockers for the treatment of hypertension
Efficacy and Safety of Combined vs. Single Renin-Angiotensin-Aldosterone System Blockade in Chronic Kidney Disease: A Meta-Analysis
Deficiency of T-type Ca<sup>2+</sup> channels Ca<sub>v</sub>3.1 and Ca<sub>v</sub>3.2 has no effect on angiotensin II-induced hypertension but differential effect on plasma aldosterone in mice
Multifunctional L/N- and L/T-type calcium channel blockers for kidney protection
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
Functional Importance of L- and P/Q-Type Voltage-Gated Calcium Channels in Human Renal Vasculature
The N- and L-Type Calcium Channel Blocker Cilnidipine Suppresses Renal Injury in Dahl Rats Fed a High-Sucrose Diet, an Experimental Model of Metabolic Syndrome
Comparison of L-type and mixed L- and T-type calcium channel blockers on kidney injury caused by deoxycorticosterone-salt hypertension in rats
Vascular Smooth Muscle Cells Express the α<sub>1A</sub>Subunit of a P-/Q-Type Voltage-Dependent Ca<sup>2+</sup>Channel, and It Is Functionally Important in Renal Afferent Arterioles
Reno-protective effects of renin–angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis
Characterization of three types of calcium channel in the luminal membrane of the distal nephron
T-type voltage-gated calcium channels regulate the tone of mouse efferent arterioles
Mechanistic View of Renal Protective Action of Calcium Channel Blockade
Preserving renal function in adults with hypertension and diabetes: A consensus approach
Pedal edema—not all dihydropyridine calcium antagonists are created equal
New Role of P/Q-type Voltage-gated Calcium Channels
A new-generation N/L-type calcium channel blocker leads to less activation of the renin–angiotensin system compared with conventional L type calcium channel blocker
Functional disorders of the sympathetic nervous system in mice lacking the α <sub>1B</sub> subunit (Ca <sub>v</sub> 2.2) of N-type calcium channels
Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials
Progression of Chronic Kidney Disease: The Role of Blood Pressure Control, Proteinuria, and Angiotensin-Converting Enzyme Inhibition: A Patient-Level Meta-Analysis
Systemic and glomerular hypertension and progression of chronic renal disease: The dilemma of nephrosclerosis
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
The α<sub>1G</sub>-subunit of a voltage-dependent Ca<sup>2+</sup>channel is localized in rat distal nephron and collecting duct
Different Effects of L/N-Type and L-Type Calcium Channel Blockers on the Renin-Angiotensin-Aldosterone System in SHR/Izm
Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients
Differential Expression of T- and L-Type Voltage-Dependent Calcium Channels in Renal Resistance Vessels
2020 International Society of Hypertension Global Hypertension Practice Guidelines
Ca<sup>2+</sup>Channel Subtypes and Pharmacology in the Kidney
Tubular and cellular localization of the cardiac L-type calcium channel in rat kidney
Renal-Protective Effect of T- and L-Type Calcium Channel Blockers in Hypertensive Patients: An Amlodipine-to-Benidipine Changeover (ABC) Study
Inhibitory Effect of Efonidipine on Aldosterone Synthesis and Secretion in Human Adrenocarcinoma (H295R) Cells
Structure and Regulation of Voltage-Gated Ca<sup>2+</sup> Channels
Impact of renal function on cardiovascular events in elderly hypertensive patients treated with efonidipine
Benidipine, a dihydropyridine L-type/T-type calcium channel blocker, affords additive benefits for prevention of cardiorenal injury in hypertensive rats
Clinical Manifestations of Kidney Disease Among US Adults With Diabetes, 1988-2014
T-type calcium channel blockade as a therapeutic strategy against renal injury in rats with subtotal nephrectomy
CKD in the United States: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004
Benidipine reduces albuminuria and plasma aldosterone in mild-to-moderate stage chronic kidney disease with albuminuria
Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events
Cilnidipine suppresses podocyte injury and proteinuria in metabolic syndrome rats: possible involvement of N-type calcium channel in podocyte
Ca2+ Channel α1B Subunit (CaV 2.2) Knockout Mouse Reveals a Predominant Role of N-Type Channels in the Sympathetic Regulation of the Circulatory System
Molecular Basis for CA2+ Channel Diversity
Dominant Role of N-Type Ca <sup>2+</sup> Channels in Evoked Release of Norepinephrine from Sympathetic Neurons
Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy
Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease
Discovery and Development of Calcium Channel Blockers
Nomenclature of Voltage-Gated Calcium Channels
Cilnidipine Attenuates Renal Nerve Stimulation-Induced Renal Vasoconstriction and Antinatriuresis in Anesthetized Dogs.
Disparate Effects of Calcium Antagonists on Renal Microcirculation.
Effects of the T/L-type Calcium Channel Blocker Benidipine on Albuminuria and Plasma Aldosterone Concentration
Effects of L/N-Type Calcium Channel Antagonist, Cilnidipine on Progressive Renal Injuries in Dahl Salt-Sensitive Rats
N-type Calcium Channel Inhibition With Cilnidipine Elicits Glomerular Podocyte Protection Independent of Sympathetic Nerve Inhibition
Data Provider (Database)
国立情報学研究所 : CiNii Research
Original Data Provider (Database)
学術機関リポジトリデータベース
雑誌記事索引データベース
Crossref
科学研究費助成事業データベース
科学研究費助成事業データベース
Bibliographic ID (NDL)
12289733